Abstract Background: Refugee, immigrant, and asylee populations face significant barriers to healthcare access, including linguistic, cultural, socioeconomic, and institutional challenges. The Refugee Education and Clinic Team (REACT) is a student-run free clinic in Maricopa County, Arizona, providing subacute care and referrals to federally qualified health centers (FQHCs). This study evaluates patient demographics, clinical needs, social determinants of health (SDH), and follow-up outcomes to identify barriers to long-term care integration. Methods: A retrospective chart review of all REACT patients (2022–2024) was conducted using electronic health records. Data on demographics, SDH, chief complaints, prescriptions, referrals, and follow-up outcomes were analyzed using descriptive statistics and logistic regression. Results: The cohort (n=95) was predominantly uninsured (63%) and faced significant social barriers, including food insecurity (30.5%), employment challenges (30.5%), and language barriers (28.4%). Musculoskeletal pain and general health check-ups were the most common concerns. Older patients had higher-than-expected rates of possible hypertension. Nearly 90% received primary care provider (PCP) referrals, yet follow-up rates remained low, with only 42% attending or planning to still attend the referred visit after their initial clinic visit with us. Successful phone outreach was a significant predictor (OR: 0.5, 95% CI: 0.31-0.77) of PCP visit attendance by multivariate logistic regression. Conclusion: REACT serves a unique population with distinct barriers to care. While the clinic facilitates healthcare entry, limited follow-up adherence highlights the need for enhanced outreach, geographically optimized referrals, and integrated allied health services to improve care continuity.
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic Enterprise Experience, updated.
1089 Background: T-DXd has become an important treatment option in mBC and other malignancies. Interstitial lung disease/pneumonitis (ILD) occurred in 10-14% of pts in the DESTINY-Breast trials (0-2% G5 ILD), and with potential lower incidence/severity in earlier line settings (Krop et al, ASCO 2023). We previously reported the Mayo Clinic Rochester, MN experience with T-DXd related ILD in mBC (Hoppenworth et al, ASCO 2024). Here, we expand the data to include patients treated at all locations of the Mayo Clinic Enterprise. Methods: We retrospectively identified pts with mBC who received ≥1 dose of T-DXd across the Mayo Clinic enterprise (Rochester, MN; Mayo Clinic Health System locations in MN/WI; Scottsdale, AZ; and Jacksonville, FL) between July 2022-December 2023. Demographic, mBC characteristics, and pulmonary clinical variables were abstracted from the clinical records. Data were summarized using descriptive statistics. Diagnosis of ILD was determined by treating clinicians, and severity was approximated to CTCAE V5 based on clinical documentation. Results: 252 pts with mBC received T-DXd during the study period. The majority were Caucasian (86%) and female (99%) with a median age of 63. 91 pts (36%) were current/formers smokers and 97 (39%) had prior pulmonary comorbidities. The majority had HER2 low (155, 62%) and HR positive (164, 65%) mBC. 35 (14%) developed any grade ILD [G1: 6 (17%), G2: 13 (37%), G3: 3 (8.6%), G4: 3 (8.6%), G5: 10 (29%)], with 15 (43%) presenting with ≥G3. 29 (83%) presented with at least 1 symptom (cough or SOB). Among those with previous pulmonary toxicity, 4 (33%) had previous pneumonitis in the ILD cohort. The median prior lines of all therapies (including endocrine therapy) were 5, with a median of 3 prior lines of chemotherapy in both the ILD (range 1-13) and non-ILD cohorts (range 1-13). Median onset to any grade ILD was 7 cycles. 20 pts (57%) received steroids for ILD. 14 (40%) had a bronchoscopy, all had a CT chest, 16 (46%) were hospitalized, 7 (20%) were intubated and 1 (3%) had a lung biopsy. Pts with G5 ILD had a median of 3 lines of chemo and a median of 8 cycles prior to onset of ILD, compared to 3 lines of chemo and a median of 7 cycles for those with G1-4 ILD. G5 pts were all Caucasian females, 5 were former smokers, 5 were non-smokers, 1 had a history of pneumonitis. T-DXd was rechallenged in 4 pts (G1-2 ILD) without ILD recurrence. Conclusions: In this retrospective case series,14% of pts treated with T-DXd experienced any grade ILD (4% G5) which is in alignment with the rate observed in the pivotal DESTINY-Breast trials, though with higher rates of G5 toxicity. Among those with ILD, increased lines of therapy were not associated with increased risk. Further research is needed to correlate risk.